News

ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias. Its proprietary pTau217 antibody, integral to the most advanced and widely available blood-based tests, is transforming Alzheimer’s disease research, diagnosis, treatment and monitoring.

Stay Connected

Want to learn more about ALZpath?

General Inquiries:
inquiry@alzpath.bio

Site Designed and Developed by Meld Marketing

ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics

Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis

ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor

ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

ALZpath Appoints Mike Banville as CEO

Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research

ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024

New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis

ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease

ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer

ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research

New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain

ALZpath Announces New Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay

ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood

Stay Connected